AZD 8601

Drug Profile

AZD 8601

Alternative Names: AZD-8601

Latest Information Update: 16 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca; Moderna Therapeutics
  • Developer AstraZeneca; Moderna Therapeutics; The Karolinska Institutet/AstraZeneca Integrated Cardio Metabolic Centre
  • Class Cardiovascular therapies; RNA; Small molecules
  • Mechanism of Action Vascular endothelial growth factor A expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Heart failure
  • Phase I Type 2 diabetes mellitus
  • Preclinical Cardiovascular disorders; Metabolic disorders

Most Recent Events

  • 14 Dec 2017 Phase-II clinical trials in Heart failure in Finland (Intracardiac) (EudraCT2017-002690-19)
  • 14 Sep 2017 Moderna Therapeutics submitted a clinical trial application in Europe for a phase IIa trial
  • 14 Sep 2017 Moderna Therapeutics plans a phase IIa trial for Cardiovascular disorders in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top